Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: A register-based cohort study

Cancer Medicine

Volumn 4, Issue 8, 2015, Pages 1303-1308

  Suhrke, Pål ^a,b   Zahl, Per Henrik ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b VESTFOLD HOSPITAL TRUST   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Breast cancer; Hormone therapy; Mammography and invasive lobular carcinoma

Indexed keywords

ESTRADIOL; ESTRIOL; ESTROGEN; PROGESTERONE; TIBOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; FEMALE; HAZARD RATIO; HORMONAL THERAPY; HUMAN; INTRADUCTAL CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSE; NORWAY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; BREAST NEOPLASMS; CANCER STAGING; HEALTH SURVEY; HISTORY; HORMONE SUBSTITUTION; INCIDENCE; MIDDLE AGED; REGISTER; RISK;

BREAST NEOPLASMS; FEMALE; HISTORY, 21ST CENTURY; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MAMMOGRAPHY; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; NORWAY; PUBLIC HEALTH SURVEILLANCE; REGISTRIES; RISK;

EID: 85006189416     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.474     Document Type: Article

References (21)

1. Jørgensen, K. J., and P. C. Gøtzsche . 2009. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339:b2587.
2. Hofvind, S., B. Moller, S. Thoresen, and G. Ursin . 2006. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int. J. Cancer 118:3112-3117.
3. Bakken, K., E. Alsaker, A. E. Eggen, and E. Lund . 2004. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int. J. Cancer 112:130-134.
4. 1997. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047-1059.
5. Ross, R. K., A. Paganini-Hill, P. C. Wan, and M. C. Pike . 2000. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92:328-332.
6. Magnusson, C., J. A. Baron, N. Correia, R. Bergström, H. O. Adami, and I. Persson . 1999. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer 81:339-344.
7. Schairer, C., J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover . 2000. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491.
8. Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
9. Beral, V. 2003. Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419-427.
10. Suhrke, P., J. Mæhlen, and P. H. Zahl . 2012. Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway. Breast J. 18:549-556.
11. Kumle, M. 2008. Declining breast cancer incidence and decreased HRT use. Lancet 372:608-610.
12. Hofvind, S., S. Sakshaug, G. Ursin, and S. Graff-Iversen . 2012. Breast cancer incidence trends in Norway-explained by hormone therapy or mammographic screening? Int. J. Cancer 130:2930-2938.
13. Zahl, P. H., B. H. Strand, and J. Maehlen . 2004. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 328:921-924.
14. Hofvind, S., B. Geller, P. M. Vacek, S. Thoresen, and P. Skaane . 2007. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur. J. Epidemiol. 22:447-455.
15. Weedon-Fekjær, H., K. Bakken, L. J. Vatten, and S. Tretli . 2012. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ344:e299. doi: 10.1136/bmj.e299
16. Chen, C. L., N. S. Weiss, P. Newcomb, W. Barlow, and E. White . 2002. Hormone replacement therapy in relation to breast cancer. JAMA 287:734-741.
17. Daling, J. R., K. E. Malone, D. R. Doody, L. F. Voigt, L. Bernstein, R. J. Coates, etal. 2002. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455-2464.
18. Newcomer, L. M., P. A. Newcomb, J. D. Potter, Y. Yasui, A. Trentham-Dietz, B. E. Storer, etal. 2003. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14:225-233.
19. Li, C. I., J. R. Daling, K. L. Haugen, M. T. Tang, P. L. Porter, and K. E. Malone . 2014. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. Breast Cancer Res. Treat. 145:481-489.
20. Luo, J., B. B. Cochrane, J. Wactawski-Wende, J. R. Hunt, J. K. Ockene, and K. L. Margolis . 2013. Effects of menopausal hormone therapy on ductal carcinoma insitu of the breast. Breast Cancer Res. Treat. 137:915-925.
21. Heiss, G., R. Wallace, G. L. Anderson, A. Aragaki, S. A. Beresford, R. Brzyski, etal. 2008. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin JAMA 299:1036-1045.